Abstract
Targeting XRN1 activates an intracellular innate immune response mediated by RNA-sensing signaling and potentiates cancer immunotherapy efficacy, suggesting inhibition of RNA decay machinery as a novel strategy for cancer treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have